Vanguard Capital Management’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
Other funds holding LAB
LFCM
Vanguard Capital Management's LAB Position: Q3 2026 in Review
Vanguard Capital Management increased its Standard BioTools (LAB) stake by 2% in Q3 2026, buying an estimated $187K and bringing the position to 12,496,998 shares worth $9.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2809.
Vanguard Capital Management first reported a position in LAB in Q1 2026 and has held it in 3 quarters since. The position peaked at $11.8M in Q1 2026. 104 funds tracked by Wall St. Rank hold LAB as of Q3 2026.
- Vanguard Capital Management held 12,496,998 shares of Standard BioTools worth $9.26M as of Q3 2026.
- Vanguard Capital Management bought 244,000 Standard BioTools shares in Q3 2026, an estimated $187K.
- Standard BioTools made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2809 holding.
- Vanguard Capital Management first reported a position in Standard BioTools in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Standard BioTools position peaked at $11.8M in Q1 2026.
- 104 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.